B3. [ETR028 + ETR029] blend "1", "2", "3", or "4" (fasted) for Acute Pain

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Medpace, Cincinnati, OHAcute PainETR028, ETR029, [ETR028 + ETR029] or HCBT - Drug
Eligibility
18 - 55
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the safety and tolerability of two new drugs relative to a comparator drug, hydrocodone bitartrate hemipentahydrate. The trial will test subjects under both fasted and fed conditions, with naltrexone blockade.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Time Zero (just prior to dose) to 48 hours post dose Timepoints: pre-dose and at 0.5,1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose.

Day 8
Subjects reporting at least one Adverse Event (AE)
Day 30
Subjects reporting at least one Serious Adverse Event (SAE)
Hour 48
Pyruvate Kinase

Trial Safety

Safety Progress

1 of 3

Similar Trials

Side Effects for

Hydrocodone/Acetaminophen
3%Vomiting
2%Hematometra requiring reaspiration
This histogram enumerates side effects from a completed 2011 Phase 4 trial (NCT01330459) in the Hydrocodone/Acetaminophen ARM group. Side effects include: Vomiting with 3%, Hematometra requiring reaspiration with 2%.

Trial Design

17 Treatment Groups

A2. <= 80mg HCBT
1 of 17
A1.1. 10 mg HCBT
1 of 17
A1.1. 5 mg HCBT
1 of 17
B3. [ETR028 + ETR029] blend "1", "2", "3", or "4" (fasted)
1 of 17
B6. [ETR028 + ETR029] blend "1", "2", "3", or "4"
1 of 17
B2. [ETR028 + ETR029] blend "4"
1 of 17
A1.1. 30 mg ETR028 Sentinel
1 of 17
B4. [ETR028 + ETR029] blend "1", "2", "3", or "4"
1 of 17
A1.2. 30 mg ETR028
1 of 17
A1.1. 30 mg ETR029 Sentinel
1 of 17
B1. [ETR028 + ETR029] blend "2"
1 of 17
B2. [ETR028 + ETR029] blend "3"
1 of 17
B5. [ETR028 + ETR029] blend "1", "2", "3", or "4"
1 of 17
A1.2. 30 mg ETR029
1 of 17
A2. <=60mg ETR028
1 of 17
B1. [ETR028 + ETR029] blend "1"
1 of 17
B3. [ETR028 + ETR029] blend "1", "2", "3", or "4" (fed)
1 of 17

Active Control

Experimental Treatment

78 Total Participants · 17 Treatment Groups

Primary Treatment: B3. [ETR028 + ETR029] blend "1", "2", "3", or "4" (fasted) · No Placebo Group · Phase 1

B3. [ETR028 + ETR029] blend "1", "2", "3", or "4" (fasted)
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
B6. [ETR028 + ETR029] blend "1", "2", "3", or "4"
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
B2. [ETR028 + ETR029] blend "4"
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
A1.1. 30 mg ETR028 Sentinel
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
B4. [ETR028 + ETR029] blend "1", "2", "3", or "4"
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
A1.2. 30 mg ETR028
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
A1.1. 30 mg ETR029 Sentinel
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
B1. [ETR028 + ETR029] blend "2"
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
B2. [ETR028 + ETR029] blend "3"
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
B5. [ETR028 + ETR029] blend "1", "2", "3", or "4"
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
A1.2. 30 mg ETR029
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
A2. <=60mg ETR028
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
B1. [ETR028 + ETR029] blend "1"
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
B3. [ETR028 + ETR029] blend "1", "2", "3", or "4" (fed)
Drug
Experimental Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
A2. <= 80mg HCBT
Drug
ActiveComparator Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
A1.1. 10 mg HCBT
Drug
ActiveComparator Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug
A1.1. 5 mg HCBT
Drug
ActiveComparator Group · 1 Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: time zero (just prior to dose) to 48 hours post dose timepoints: pre-dose and at 0.5,1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose.

Who is running the clinical trial?

Ohio Third FrontierOTHER
5 Previous Clinical Trials
613 Total Patients Enrolled
Medpace, Inc.Industry Sponsor
89 Previous Clinical Trials
28,541 Total Patients Enrolled
Elysium Therapeutics, Inc.Lead Sponsor
National Institute on Drug Abuse (NIDA)NIH
2,269 Previous Clinical Trials
2,032,273 Total Patients Enrolled
1 Trials studying Acute Pain
155 Patients Enrolled for Acute Pain
Charles River LabsUNKNOWN
Lynn Webster, MDStudy DirectorElysium Therapeutics, Inc.
5 Previous Clinical Trials
441 Total Patients Enrolled
Leela Vrishabhendra, MDPrincipal InvestigatorMedpace, Inc.
5 Previous Clinical Trials
376 Total Patients Enrolled

Eligibility Criteria

Age 18 - 55 · All Participants · 15 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Has the FDA confirmed permission for A2. <=60mg ETR028?

"Due to the lack of data on A2. <=60mg ETR028's efficacy and safety, our team at Power gave this drug a rating of 1 out of 3." - Anonymous Online Contributor

Unverified Answer

Could I be a potential subject in this research project?

"This medical trial is seeking 78 individuals to join, all of whom should suffer from acute pain and be between 18-55 years old." - Anonymous Online Contributor

Unverified Answer

Does this research encompass individuals aged 35 and older?

"This trial's prerequisite for entry is that the participant should be between 18 to 55 years of age. However, there are 20 more trials specifically designed for minors and 116 options available for seniors above 65." - Anonymous Online Contributor

Unverified Answer

Are there any opportunities for participants in this trial at present?

"Data hosted on clinicaltrials.gov attests that this medical trial, which commenced on September 27th 2022, is actively enrolling participants. The study's information was most recently modified in October 7th of the same year." - Anonymous Online Contributor

Unverified Answer

What is the aggregate size of the population involved in this clinical investigation?

"Affirmative. According to clinicaltrials.gov, this study is currently recruiting participants who meet the criteria. It was initially posted on September 27th 2022 and has been recently updated as of October 7th 2022. A total of 78 subjects are needed across 1 site for this trial." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.